key: cord-0818146-3qne90pv
authors: Auld, Sara C.; Caridi-Scheible, Mark; Blum, James M.; Robichaux, Chad; Kraft, Colleen; Jacob, Jesse T.; Jabaley, Craig S.; Carpenter, David; Kaplow, Roberta; Hernandez-Romieu, Alfonso C.; Adelman, Max W.; Martin, Greg S.; Coopersmith, Craig M.; Murphy, David J.
title: ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019
date: 2020-05-26
journal: Crit Care Med
DOI: 10.1097/ccm.0000000000004457
sha: 9d66d2edfc1127782678ba62fe2687f9c7a527f7
doc_id: 818146
cord_uid: 3qne90pv

To determine mortality rates among adults with critical illness from coronavirus disease 2019. DESIGN: Observational cohort study of patients admitted from March 6, 2020, to April 17, 2020. SETTING: Six coronavirus disease 2019 designated ICUs at three hospitals within an academic health center network in Atlanta, Georgia, United States. PATIENTS: Adults greater than or equal to 18 years old with confirmed severe acute respiratory syndrome-CoV-2 disease who were admitted to an ICU during the study period. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Among 217 critically ill patients, mortality for those who required mechanical ventilation was 35.7% (59/165), with 4.8% of patients (8/165) still on the ventilator at the time of this report. Overall mortality to date in this critically ill cohort is 30.9% (67/217) and 60.4% (131/217) patients have survived to hospital discharge. Mortality was significantly associated with older age, lower body mass index, chronic renal disease, higher Sequential Organ Failure Assessment score, lower Pao(2)/Fio(2) ratio, higher d-dimer, higher C-reactive protein, and receipt of mechanical ventilation, vasopressors, renal replacement therapy, or vasodilator therapy. CONCLUSIONS: Despite multiple reports of mortality rates exceeding 50% among critically ill adults with coronavirus disease 2019, particularly among those requiring mechanical ventilation, our early experience indicates that many patients survive their critical illness.

based upon a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction assay, performed either by the Georgia Department of Public Health, a referral laboratory, or the hospital-based clinical laboratory. During the study period, ICU capacity enabled the timely admission of all patients requiring critical care to a COVID-ICU. Further, all patients admitted to a COVID-ICU were cared for by a traditional ICU care team led by a critical care-trained attending physician with standard (i.e., pre-COVID) ICU staffing ratios. There were no critical shortages in medications, ventilators, dialysis machines, or other critical care equipment. Patient data, including sociodemographic information, clinical data, and laboratory data, were obtained from the electronic medical record.

Data were abstracted through May 7, 2020. Data were analyzed using a chi-square or Wilcoxon rank-sum test for categorical and continuous variables, respectively, with a two-sided p value of less than 0.05 considered statistically significant (Stata Version 12.1; StataCorp LLC, College Station, TX). This study was approved by the Emory University Institutional Review Board.

From March 6, 2020, to April 17, 2020, 217 critically ill adults with COVID-19 infection were admitted to the ICU (Fig. 1A) 

Initial ICU clinical findings, critical care interventions, and outcomes are summarized in Table 2 . At admission to the ICU, the median Sequential Organ Failure Assessment (SOFA) score was 7 (IQR, 5-11), the median d-dimer was 1,731 ng/mL (IQR, 934-6,948 ng/mL; upper limit of normal 298 ng/mL), and the median C-reactive protein was 190 mg/L (IQR, 126-262 mg/L; upper limit of normal 10 mg/L). The median initial Pao 2 /Fio 2 ratio was 132 (IQR, 100-178).

There were 165 patients (76.0%) who received invasive mechanical ventilation. The median static lung compliance on the first day of intubation was 34 mL/cm H 2 O (IQR, 28-46 mL/ cm H 2 O). A total of 143 patients (65.9%) required vasopressor support for shock and 63 (29.0%) required renal replacement therapy, either in the form of continuous renal replacement therapy or intermittent hemodialysis. Use of inhaled pulmonary vasodilators was relatively uncommon (22 [10.1%]) and four patients (1.8%) received extracorporeal membrane oxygenation. Overall, 114 patients (52.5%) received at least one dose of hydroxychloroquine and 49 patients (22.6%) were enrolled in the National Institutes of Health-funded adaptive clinical treatment trial (ACTT) of remdesivir (ClinicalTrials. gov NCT04280705).

Among the 217 patients in the cohort, 147 (67.7%) have been transferred alive from the ICU, 62 died (28.6%) in the ICU (five additional deaths occurred among patients transferred to the floor), and 8 (3.7%) remain in the ICU, all of whom are still mechanically ventilated (Fig. 1A) . Three of the patients transferred from the ICU went directly to a long-term acute care facility while still receiving mechanical ventilation through a tracheostomy. The median ICU length of stay for patients still in the ICU is 32 days (IQR, 28-41 d). Among patients who received invasive mechanical ventilation, ICU mortality is 33.9% (56/165) and hospital mortality is 35.7% (59/165) (Fig. 1B) .

The median age of patients who died was significantly older than for those who survived (71 yr [IQR, 64-78 yr] vs 61 yr [IQR, 52-69 yr]; p < 0.001) ( Table 1 ). There was no difference in survival between sexes, but patients who died were less likely to be morbidly obese. Although patients of Asian race did have higher mortality, there were only seven Asian patients in the cohort. Patients with either chronic kidney disease (stage 3 or higher) or end-stage renal disease requiring hemodialysis also had higher mortality.

Patients who died had a higher SOFA score on ICU admission (median, 10; IQR, 7-13) than those who survived (median, 7; IQR, 4-10; p < 0.001) ( Table 2 ). Median d-dimer values were more than two times higher in those who died than those who survived (3,451 [IQR, 1,401-19,468] vs 1,570 [IQR, 905-4,261]; p 0.005). Similarly, the initial C-reactive protein and Pao 2 /Fio 2 ratios were significantly worse in patients who died in the ICU (p 0.045 and < 0.001, respectively). Compared to those who survived, patients who died in the ICU were more likely to have respiratory failure requiring invasive mechanical ventilation (90.3% vs 68.7%; p < 0.001), shock requiring vasopressors (90.3% vs 53.7%; p <0.001), renal failure requiring renal replacement therapy (53.2% vs 18.4%; p <0.001), and receive inhaled vasodilators (19.3% vs 6.1%; p < 0.001).

Overall, mortality among patients who received vasopressors was 39.2% (56/143), while 33 of 63 patients (52.4%) with renal failure requiring renal replacement therapy died. Twelve of the 22 patients (54.5%) who received inhaled vasodilator for refractory hypoxemia died. Among the 62 patients who died in the ICU, including three patients who had an advance directive not to be intubated, the median time from ICU admission to death was 9 days (IQR, 5-14 d).

Our early experience with this large cohort of critically ill patients with COVID-19 demonstrates a mortality rate of 30.9% overall, which is substantially lower than the 50-97% reported in the published literature to date (1) (2) (3) (4) (5) (6) . Additionally, the 35.7% mortality for the approximately three-quarters of patients in our cohort who required mechanical ventilation is also markedly lower than previous reports. These data indicate that a majority of critically ill patients with COVID-19

can have good clinical outcomes and support the ongoing use of mechanical ventilation for patients with acute respiratory failure.

In some of the earliest reports of COVID-19 from Wuhan, mortality rates among those admitted to ICUs ranged from 52% to 62% and increased to 86-97% among those requiring invasive mechanical ventilation (5, 6, 15, 16) . In more recent data from the United Kingdom, 67% of those who had received mechanical ventilation died, as compared with 22% of patients intubated with viral pneumonia in the preceding 3 years (3). Early reports of smaller cohorts from Seattle, where some of the first COVID-19 outbreaks occurred in the United States, indicated that 50-67% of patients admitted to the ICU and 71-75% of those receiving invasive mechanical ventilation died (1, 2) . A recently published report from New York found 24.5% mortality among those who required mechanical ventilation, but with 72.2% of patients still admitted to the hospital (4) .

Taken together, these reports have raised concerns that survival among those receiving mechanical ventilation is exceedingly poor (11) (12) (13) (14) . In contrast to the majority of prior reports, our data provide evidence that mortality rates in COVID-19 can be comparable to those seen with ARDS and other infectious pneumonias (7) (8) (9) (10) .

In our cohort, mortality was associated with older age, with 42.5% mortality in those age 65 and above as compared with 11.3% in those under age 55. Mortality was also associated with severity of illness on arrival to the ICU and need for ICU interventions including mechanical ventilation, vasopressor support, renal replacement therapy, and inhaled vasodilators. Approximately half of our cohort received at least one dose of hydroxychloroquine and nearly onequarter received at least one dose of a study drug as part of the ACTT trial (remdesivir vs placebo), but there was no difference in survival for either of those groups. Finally, although eight patients (3.7%) are still admitted to the ICU at the time of this report, 131 (60.4%) have been discharged from the hospital.

Several local and regional considerations may have influenced the observed outcomes. First, the arrival and peak of the COVID-19 pandemic in Georgia were later than in many of the regions from earlier reports. This delay provided time to establish organizational structures, acquire equipment, prepare personnel, create consensus-driven clinical protocols, and align resources across a large healthcare system. In addition, while patient volumes did merit the redesignation of several specialty ICUs as COVID-ICUs, all critically ill patients with COVID-19 were admitted to preexisting ICUs and cared for by critical care teams with experience managing acute respiratory failure and at standard patient-to-provider ratios. Further, while an analysis of the impact of clinical interventions on survival is beyond the scope of this brief report, our internal 

In a cohort of critically ill adults with COVID-19, we report an early mortality rate of 30.9% overall and 35.7% for patients who received mechanical ventilation. Although there may be a several factors underlying these findings, these results suggest that most patients with acute respiratory failure from COVID-19 may recover, even with severe disease requiring intubation and mechanical ventilation. 

Covid-19 in critically ill patients in the Seattle region -case series

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Intensive Care National Audit & Research Centre: ICNARC Report on COVID-19 in Critical Care

and the Northwell COVID-19 Research Consortium: Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Pandemic 2009 influenza A in Argentina

Critically ill patients with 2009 influenza A(H1N1) in Mexico

LUNG SAFE Investigators; ESICM Trials Group: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries

Mortality rates for patients with acute lung injury/ARDS have decreased over time

Vasopressor days, median (IQR)

CRRT/HD days, median (IQR)

Outcomes, median (IQR)

CRRT = continuous renal replacement therapy, HD = hemodialysis, IQR = interquartile range. a p: χ 2 or Wilcoxon rank-sum test comparing those who survived vs died in the ICU. www.ccmjournal.org XXX 2020 • Volume XX • Number XXX

Respiratory support in novel coronavirus disease (COVID-19) patients, with a focus on resource-limited settings

With Ventilators Running Out, Doctors Say the Machines Are Overused for Covid-19

Some Doctors Question Wisdom of Using Ventilators on Coronavirus Patients

Ventilators Are No Panacea for Critically Ill COVID-19

National Public Radio

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A singlecentered, retrospective, observational study

We would like to extend our most profound thanks and gratitude to our colleagues in the Emory Critical Care Center and